Millions of people around the world have received two shots of Sinovac, a Chinese-made inactivated vaccine used in 48 countries to reduce the prevalence of COVID-19.
However, these vaccinations alone do not help against the widely distributed variants of Omicron, and new studies by researchers at Yale University and the Dominican Republic have been shown.Results will be published in the journal Nature medicine..
Analysis of sera from 101 people in the Dominican Republic revealed that Omicron infection Neutralizing antibody Among those who received the standard two-shot regimen of the Sinovac vaccine. The antibody level against Omicron is amplifier Pfizer-A shot of the mRNA vaccine produced by BioNTech.
However, when researchers compared these samples to serum samples stored at Yale University, even those who received two Sinovac shots and boosters. Antibody level This was about the same as those who received the mRNA vaccine twice but did not receive the booster vaccine. Other studies have shown that booster-free two-shot mRNA regimens provide limited protection against Omicron.
Researchers also found that individuals infected with an early strain of SARS-Cov-2 virus had little immune protection against Omicron.
The findings could complicate global efforts to combat the Omicron strain, which has replaced the more dangerous but less contagious Delta strain as the most predominant circulating virus in the world. Akiko Iwasaki, a professor of immunobiology and lead author of the paper, Waldemar Von Zedtwitz, clearly needs additional booster shots (or two in some cases) in regions of the world where Sinovac shots are the primary source of vaccination. It states that there is.
“We know that two mRNA vaccines do not provide sufficient protection against Omicron infection, so booster shots are clearly needed in this population,” Iwasaki said.
Omicron has 36 mutations, which has proven to be particularly problematic in combat. Spike protein Researchers say on the surface that the virus uses to invade cells. Existing mRNA vaccines are designed to trigger an antibody response when a peplomer is recognized.
However, Iwasaki emphasized that the human immune system still has other weapons that can be used against COVID-19, such as T cells that can attack, kill, and prevent infected cells. Severe illness..
“But we need antibodies to prevent the infection and delay of the virus,” she said.
Both Carolina Lucas and Valter Silva Monteiro of Yale School of Medicine are co-lead authors of this paper. Eddy Perez-Then of the Ministry of Health of the Dominican Republic and Marija Miric of Two Oceans Health in Santo Domingo are co-authors.
Eddy Pérez-Thenetal, Neutralizing Antibodies to SARS-CoV-2 Delta and Omicron Variants After Heterologous CoronaVac and BNT162b2 Booster Vaccination, Nature medicine (2022). DOI: 10.1038 / s41591-022-01705-6
Quote: Sinovac: Vaccines used in many parts of the world do not match the Omicron variant (January 20, 2022), https: //medicalxpress.com/news/2022-01-sinovac-vaccine-world-omicron- Obtained from variant on January 20, 2022. html
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.
Vaccine used in much of the world no match for Omicron variant Source link Vaccine used in much of the world no match for Omicron variant
The post Vaccine used in much of the world no match for Omicron variant appeared first on California News Times.